Supplement 1. Multivariable adjusted association between serum lipid levels and frequency-specific hearing loss after excluding those study subjects who reported taking lipid lowering agents ( $\mathrm{N}=9,257$ )

| Variable | Low-frequency hearing loss |  |  |  | High-frequency hearing loss |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | No | Yes | OR (95\% Cl)* | P -value | No | Yes | OR (95\% Cl) | P -value |
| Total cholesterol (mg/dL) |  |  |  |  |  |  |  |  |
| Q1 (<171) | 1,566 | 718 | 1 |  | 810 | 1,474 | 1 |  |
| Q2 (172-193) | 1,700 | 631 | 0.91 (0.74-1.11) | 0.356 | 875 | 1,456 | 1.05 (0.86-1.27) | 0.647 |
| Q3 (194-217) | 1,683 | 625 | 0.90 (0.75-1.08) | 0.250 | 866 | 1,442 | 0.97 (0.80-1.19) | 0.777 |
| Q4 ( $\geq 218$ ) | 1,683 | 651 | 0.93 (0.77-1.13) | 0.465 | 883 | 1,451 | 0.96 (0.79-1.16) | 0.653 |
| Per $1 \mathrm{mmol} / \mathrm{L}$ increase | 6,632 | 2,625 | 1.16 (0.93-1.44) | 0.191 | 3,434 | 5,823 | 1.21 (1.00-1.46) | 0.050 |
| Triglyceride ( $\mathrm{mg} / \mathrm{dL}$ ) |  |  |  |  |  |  |  |  |
| Q1 (<77) | 1,661 | 592 | 1 |  | 992 | 1,261 | 1 |  |
| Q2 (77-113) | 1,672 | 690 | 0.95 (0.78-1.16) | 0.595 | 922 | 1,440 | 0.92 (0.75-1.14) | 0.454 |
| Q3 (114-169) | 1,643 | 683 | 0.87 (0.71-1.05) | 0.150 | 802 | 1,524 | 0.86 (0.70-1.05) | 0.128 |
| Q4 ( $\geq 170$ ) | 1,656 | 660 | 0.94 (0.76-1.15) | 0.530 | 718 | 1,598 | 1.04 (0.85-1.27) | 0.681 |
| Per $1 \mathrm{mmol} / \mathrm{L}$ increase | 6,632 | 2,625 | 0.98 (0.94-1.02) | 0.300 | 3,434 | 5,823 | 0.98 (0.95-1.01) | 0.122 |
| High-density lipoprotein cholesterol (mg/dL) |  |  |  |  |  |  |  |  |
| Q1 (M: <38.21, F: <42.28) | 1,499 | 728 | 1 |  | 667 | 1,560 | 1 |  |
| Q2 (M: 38.21-44.31, F: 42.28-49.34) | 1,721 | 679 | 0.92 (0.76-1.12) | 0.421 | 894 | 1,506 | 0.77 (0.63-0.95) | 0.014 |
| Q3 (M: 44.32-52.37, F: 49.35-57.42) | 1,712 | 614 | 0.98 (0.81-1.19) | 0.846 | 939 | 1,387 | 0.78 (0.64-0.95) | 0.014 |
| Q4 (M: $\geq 52.38, \mathrm{~F}: \geq 57.43$ ) | 1,700 | 604 | 0.96 (0.80-1.17) | 0.696 | 934 | 1,370 | 0.77 (0.63-0.94) | 0.011 |
| Per $1 \mathrm{mmol} / \mathrm{L}$ increase | 6,632 | 2,625 | 0.88 (0.69-1.12) | 0.285 | 3,434 | 5,823 | 0.76 (0.61-0.94) | 0.011 |
| Low-density lipoprotein cholesterol (mg/dL) |  |  |  |  |  |  |  |  |
| Q1 (<95.94) | 1,615 | 699 | 1 |  | 806 | 1,508 | 1 |  |
| Q2 (95.94-116.75) | 1,676 | 639 | 1.00 (0.82-1.24) | 0.966 | 875 | 1,440 | 0.95 (0.77-1.18) | 0.656 |
| Q3 (116.76-139.05) | 1,685 | 628 | 0.90 (0.76-1.07) | 0.213 | 872 | 1,441 | 0.89 (0.73-1.09) | 0.266 |
| Q4 ( $\geq 139.06$ ) | 1,656 | 659 | 0.87 (0.71-1.06) | 0.154 | 881 | 1,434 | 0.82 (0.67-1.01) | 0.061 |
| Per $1 \mathrm{mmol} / \mathrm{L}$ increase | 6,632 | 2,625 | 0.83 (0.67-1.03) | 0.097 | 3,434 | 5,823 | 0.79 (0.65-0.96) | 0.017 |

[^0]OR, odds ratio; Cl , confidence interval; $M$, male; F , female.
*OR and $95 \% \mathrm{Cl}$ was estimated by multiple logistic regression analysis after adjusting for age, sex, hypertension, diabetes, smoking, alcohol consumption, education level, physical activity, household income, and noise exposure.


[^0]:    Values are presented as number or OR ( $95 \% \mathrm{CI}$ ), unless otherwise stated.

